$2.48T
Total marketcap
$66.33B
Total volume
BTC 50.33%     ETH 15.94%
Dominance

Teva Pharmaceutical Industries Limited TEVA.VI Stock

12.4 EUR {{ price }} -3.875969% {{change_pct}}%
COUNTRY
Austria
Exchange
Vienna
Market Cap
14.55B EUR
LOW - HIGH [24H]
12.4 - 13.1 EUR
VOLUME [24H]
0 EUR
{{ volume }}
P/E Ratio
0
Earnings per share
-0.46 EUR

Teva Pharmaceutical Industries Limited Price Chart

Teva Pharmaceutical Industries Limited TEVA.VI Financial and Trading Overview

Teva Pharmaceutical Industries Limited stock price 12.4 EUR
Previous Close 6.98 EUR
Open 6.98 EUR
Bid 6.84 EUR x 0
Ask 7.08 EUR x 0
Day's Range 6.98 - 6.98 EUR
52 Week Range 6.7 - 10.95 EUR
Volume 0 EUR
Avg. Volume 0 EUR
Market Cap 7.94B EUR
Beta (5Y Monthly) 1.180985
PE Ratio (TTM) N/A
EPS (TTM) -0.46 EUR
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est N/A

TEVA.VI Valuation Measures

Enterprise Value 27.37B EUR
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) 0.5322992
Price/Book (mrq) 0.99501073
Enterprise Value/Revenue 1.834
Enterprise Value/EBITDA 7.234

Trading Information

Teva Pharmaceutical Industries Limited Stock Price History

Beta (5Y Monthly) 1.180985
52-Week Change -5.16%
S&P500 52-Week Change 20.43%
52 Week High 10.95 EUR
52 Week Low 6.7 EUR
50-Day Moving Average 7.49 EUR
200-Day Moving Average 8.52 EUR

TEVA.VI Share Statistics

Avg. Volume (3 month) 0 EUR
Avg. Daily Volume (10-Days) 1 EUR
Shares Outstanding 1.12B
Float 1.11B
Short Ratio N/A
% Held by Insiders 0%
% Held by Institutions 51.06%
Shares Short N/A
Short % of Float N/A
Short % of Shares Outstanding N/A

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2022
Most Recent Quarter (mrq) March 31, 2023
Next Fiscal Year End December 31, 2023

Profitability

Profit Margin -10.74%
Operating Margin (ttm) 16.71%
Gross Margin 45.66%
EBITDA Margin 25.35%

Management Effectiveness

Return on Assets (ttm) 3.44%
Return on Equity (ttm) -17.93%

Income Statement

Revenue (ttm) 14.92B EUR
Revenue Per Share (ttm) 13.42 EUR
Quarterly Revenue Growth (yoy) 0%
Gross Profit (ttm) 6.97B EUR
EBITDA 3.78B EUR
Net Income Avi to Common (ttm) -1603000064 EUR
Diluted EPS (ttm) -1.34
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 2.14B EUR
Total Cash Per Share (mrq) 1.91 EUR
Total Debt (mrq) 21.04B EUR
Total Debt/Equity (mrq) 244.29 EUR
Current Ratio (mrq) 1.105
Book Value Per Share (mrq) 7.015

Cash Flow Statement

Operating Cash Flow (ttm) 1.49B EUR
Levered Free Cash Flow (ttm) 2.62B EUR

Profile of Teva Pharmaceutical Industries Limited

Country Austria
State N/A
City Tel Aviv
Address 124 Dvora Hanevi’a Street
ZIP 6944020
Phone 972 3 914 8213
Website https://www.tevapharm.com
Industry Drug Manufacturers-Specialty & Generic
Sector(s) Healthcare
Full Time Employees 34004

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also manufactures and sells active pharmaceutical ingredients, as well as provides contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. In addition, it focuses on the central nervous system (CNS), pain, respiratory, and oncology areas. The company's products portfolio in the CNS field comprises Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; and AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; respiratory therapeutic area includes ProAir RespiClick, QVAR, ProAir Digihaler, AirDuo Digihaler, ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease; and oncology therapeutic field consists of Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Q&A For Teva Pharmaceutical Industries Limited Stock

What is a current TEVA.VI stock price?

Teva Pharmaceutical Industries Limited TEVA.VI stock price today per share is 12.4 EUR.

How to purchase Teva Pharmaceutical Industries Limited stock?

You can buy TEVA.VI shares on the Vienna exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Teva Pharmaceutical Industries Limited?

The stock symbol or ticker of Teva Pharmaceutical Industries Limited is TEVA.VI.

Which industry does the Teva Pharmaceutical Industries Limited company belong to?

The Teva Pharmaceutical Industries Limited industry is Drug Manufacturers-Specialty & Generic.

How many shares does Teva Pharmaceutical Industries Limited have in circulation?

The max supply of Teva Pharmaceutical Industries Limited shares is 1.17B.

What is Teva Pharmaceutical Industries Limited Price to Earnings Ratio (PE Ratio)?

Teva Pharmaceutical Industries Limited PE Ratio is now.

What was Teva Pharmaceutical Industries Limited earnings per share over the trailing 12 months (TTM)?

Teva Pharmaceutical Industries Limited EPS is -0.46 EUR over the trailing 12 months.

Which sector does the Teva Pharmaceutical Industries Limited company belong to?

The Teva Pharmaceutical Industries Limited sector is Healthcare.